Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MHLW Designates Biogen Idec’s MS Drug Natalizumab Orphan Drug

This article was originally published in PharmAsia News

Executive Summary

The first session of Japan's Ministry of Health, Labor and Welfare's drug review board designated Biogen Idec's natalizumab an orphan drug April 25. Marketed under Tysabri, natalizumab is approved in the United States for treating relapsing forms of multiple sclerosis, and in the European Union for relapsing-remitting forms of MS. Biogen Idec Japan, the American company's Japanese subsidiary plans to start clinical trials in Japan soon. (Click here for more - Japanese language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts